To test whether USP12 downregulation is strictly associated with KRAS mutation in NSCLC, we analysed USP12 transcript levels in human LUAD tumours carrying different types of oncogenic mutations (TCGA-LUAD database). This evidence concerns the gene KRAS and neoplasm.